Navigation Links
MIT is pleased to announce that it has received a US$ 500,000 private placement from its Chinese partners
Date:6/25/2009

DENVER, CO, June 25 /PRNewswire-FirstCall/ - Medical International Technology Inc. (MDLH. PK) (http://www.mitcanada.ca http://www.mitinvest.ca), MIT is pleased to announce that it has received a US$ 500,000 private placement from its Chinese partners and a new order of 200 units. This private investment from our partners was done based on two issuances; the first for a total of US$ 250,000 at $ 0.10 and the second US$ 250,000 at $ 0.14. This investment and the new order show the beginning of a strong commitment and a step towards a successful long-term relationship between MIT and its Chinese partners.

Jiangsu Hualan MIT Medical Technology (MIT CHINA) Ltd., is actively promoting and selling MIT's unique Agro-Jet(R) needle-free jet injector for animal application, and Med-Jet(R) for human application, and is in the process of obtaining the certification for the production and sales of both models.

With the recent deaths from the outbreak of the "swine-flu" H1-N1 and the increased fear of the possible pandemic that could affect millions of people around the world, MIT and MIT China will be strongly promoting the Med-Jet(R) and the Agro-Jet(R) to help the world deal safely and efficiently with any decision that will be taken by governments for mass vaccination of humans and animals.

The MIT China venture is the beginning of a few Joint Venture agreements to be negotiated within the next several years. MIT is on its way to becoming a world leader in needle-free technology and its objective is to ensure that MIT injectors become an indispensable, environmentally friendly product for doctors and users around the world.

Medical International Technology Inc. is pleased to continue providing a safe and effective means to help prevent the spread of deadly diseases to both humans and animals through the use of the Med-Jet(R) and Agro-Jet(R) needle-free injection system.

Karim Menassa, President

On Behalf of the Board of Directors

About Medical International Technology, Inc. MIT CANADA, with offices in Montreal, is a subsidiary of Denver, Colorado-based Medical International Technology, Inc. (MIT USA), which specializes in the development, production, marketing and sale of needle-free injectors both for humans and animals, for individual and mass vaccinations.

The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development and acquisition of new product lines and services, government approval processes, the impact of competitive products or pricing a technological changes, the effect of economic conditions and other uncertainties, and the risk factors set forth from time to time in the Company's SEC reports, including but not limited to its annual report on Form 10-KSB; its quarterly reports on Forms 10-QSB; and any reports on Form 8-K. Medical International Technology Inc. takes no obligation to update or correct forward-looking statements.


'/>"/>
SOURCE MEDICAL INTERNATIONAL TECHNOLOGIES INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Concerned Shareholders of Biovail Pleased with Court Order for Biovail AGM
2. BIO Ventures for Global Health Announces Management Changes
3. Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
4. O2h and Hypoxium Announce an Agreement to Offer Hypoxiums Specialised In Vitro, Cell-Based Oncology Assays via O2hs Biology Affiliate Program
5. OmniComm Systems Announces Acquisition of EDC Business of eResearchTechnology
6. Healthy Advice Networks Announces Improved Patient Outcomes in Physicians Offices with Healthy Advice Programs
7. Spherix Announces Termination of Arla License Agreement
8. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
9. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy
10. Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM)
11. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Cambrian ... for industrial facilities, today announced that one of the nation’s fastest growing craft ... novel water-energy purchase agreement (WEPA). Under the WEPA, a first for the industrial ...
(Date:12/7/2016)... ... December 07, 2016 , ... Kara Dwyer Dodge grew up hearing stories of the sea ... in Scituate, Mass., found a sea turtle entangled in the lines of one of his ... a minor sensation because no one could remember ever seeing one so large so close ...
(Date:12/6/2016)... NJ (PRWEB) , ... December 06, 2016 , ... ... paper on December 1, 2016 asking the Federal Drug Administration (FDA) to consider ... study of OA, OARSI is concerned about the growing population of OA patients, ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... company, today announced it has acquired the assets of Theorem Clinical Research ... and focuses on clinical trial drug packaging, labeling, storage, reconciliation, and distribution ...
Breaking Biology Technology:
(Date:11/29/2016)... Lithuania , Nov. 29, 2016 /PRNewswire/ ... biometric identification and object recognition technologies, today ... (SDK) for fingerprint recognition solutions that run ... a fingerprint template using less than 128KB ... in compact devices that have limited on-board ...
(Date:11/22/2016)... November 22, 2016 According to the new market ... Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact ... MarketsandMarkets, the market is expected to grow from USD 10.74 Billion in ... 16.79% between 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ... Banks and Academics) market is to witness a value of ... the highest Compounded Annual Growth Rate (CAGR) of 10.75% is ... analysis period 2014-2020. North America is ... Europe at 9.56% respectively. Report ...
Breaking Biology News(10 mins):